Testing a new drug combo for recurrent sinus cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether combining the targeted drug becotatug vedotin with chemo can shrink recurrent adenoid cystic sinus tumors that can't be fully removed by surgery. It's for people whose tumors have a specific protein called EGFR.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your sinus cancer (adenoid cystic carcinoma) has come back and can't be fully removed with surgery.
- Your tumor tests positive for the EGFR protein.
- The tumor can be measured on scans and is at least 1 cm in size.
- You are well enough to be up and about (ECOG score 0 or 1).
- You haven't taken certain similar drugs (like those containing MMAE) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy drug called epirubicin for sinonasal adenoid cystic carcinoma. It aims to see if the drug can help shrink tumors and improve outcomes for people with advanced-stage disease.
This trial tests two cancer drugs (anlotinib and epirubicin) given before surgery to shrink advanced adenoid cystic carcinoma tumors in the sinuses. The goal is to make surgery safer and more effective for tumors that have grown into nearby structures like the skull base or eye socket.
This study looks at whether surgery followed by radiation helps people with a specific type of sinus cancer called adenoid cystic carcinoma that has grown into nearby tissues. It aims to see how well this treatment works and how safe it is.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Hear when a new Adenoid Cystic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.